HCWB

HCW Biologics Inc. [HCWB] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

HCWB Stock Summary

In the News

HCWB Financial details

Company Rating
-
Market Cap
63.54M
Income
-24.8M
Revenue
2.84M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
45
Optionable
No
Shortable
Yes
Earnings
09 May 2024
P/E
-2.1
Forward P/E
-
PEG
-0.3
P/S
14.34
P/B
1.72
P/C
-
P/FCF
-1.64
Quick Ratio
2.2
Current Ratio
2.56
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.7
EPS next Y
-
EPS next Q
-
EPS this Y
70.73%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
55.2%
EPS Q/Q
114.29%
-
-
-
-
SMA20
-3.81%
SMA50
1.18%
SMA100
-48.93%
Inst Own
-
Inst Trans
-
ROA
-55%
ROE
-64%
ROC
-0.68%
Gross Margin
20%
Oper. Margin
-721%
Profit Margin
-681%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.91-2.32
52W High
-
52W Low
-
RSI
60.32
Rel Volume
1264.32
Avg Volume
15.82K
Volume
20M
Perf Week
16.46%
Perf Month
31.84%
Perf Quarter
-53.99%
Perf Half Y
-59.02%
-
-
-
-
Beta
0.975
-
-
Volatility
0.76%, 0.81%
Prev Close
68.37%
Price
5.59
Change
70.95%

Something similar

Top by Market Cap
GOOG
BRK-B
ABEA.DE
TL0.DE
VFINX
Same Sector
OPTOCIRCUI.NS
HRTX
ILM1.DE
002393.SZ
ONC.L
Same Price Range
OPINL
1361.HK
HPK
002426.SZ
SHIP
Similar Market Cap
DECT
NMI
ESGE.TO
CIL
PR1G.DE

Company Profile

Healthcare Biotechnology
  • Volume Average 15.82K
  • Market Capitalization 63.54M
  • Employee 45
  • CEO Dr. Hing C. Wong Ph.D.
  • Headquarters Miramar,FL,US
  • IPO Date 2021-07-20
  • Website https://www.hcwbiologics.com

HCW Biologics Inc., a preclinical stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases. The company's lead products include HCW9218, which is an injectable immunotherapeutic for patients with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as pulmonary fibrosis; and HCW9302 for auto-immune diseases, such as alopecia areata and metabolic diseases. It also develops HCW9201, a cell-based therapy that is in Phase II clinical trials for the treatment of patients with relapsed/refractory acute myeloid leukemia; and HCW9206 for the treatment of acute myeloid leukemia. The company was incorporated in 2018 and is headquartered in Miramar, Florida.